Top

Published in:

Open Access 01-04-2013 | RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

The Role of Interleukin-33 in Rhinitis

Authors: Barbara Rogala, Joanna Glück

Published in: Current Allergy and Asthma Reports | Issue 2/2013

Abstract

IL-33, a member of the IL-1 cytokine family and a ligand to receptor ST2, has great potential to induce a T helper 2-type inflammatory response. IL-33 is proven to be released by epithelial cells during their injury by different environmental stimuli such as airborne allergens, viruses, and air pollutants. IL-33 acting as an endogenous danger signal is termed an alarmin. As such, this cytokine is considered to play a crucial role in an allergic inflammatory disease such as rhinitis. Recent investigations regarding the IL-33/ST2 axis involvement in Th2 inflammatory response and pathogenesis of rhinitis have been reviewed. The role of IL-33 as a novel promising therapeutic target has also been discussed.

Miller A. Role of IL-33 in inflammation and disease. J Inflammation. 2011;8:22.CrossRef

• Lloyd CM. IL-33 family members and asthma – bridging innate and adaptive immune responses. Curr Opin Immunol. 2010;22:800–806. A comprehensive review on the role of IL-33 in immune response in asthma. PubMedCrossRef

Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, Inoue I, Takeda J. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19:1279–88.PubMedCrossRef

Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP. Molecular characterization of NF-HEV, a nuclaer factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163:69–79.PubMedCrossRef

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin 1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.PubMedCrossRef

Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PLoS One. 2008;3:e3331.PubMedCrossRef

Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31:5–7.PubMedCrossRef

Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.PubMedCrossRef

Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31:84–98.PubMedCrossRef

10.

Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation of caspase-1. Proc Natl Acad Sci USA. 2009;106:9021–6.PubMedCrossRef

11.

Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420–6.PubMedCrossRef

12.

• Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67:1203–1214. This study presents a comprehensive up-to-date analysis regarding the role of IL-33/ST2 axis in the pathogenesis of allergy. PubMedCrossRef

13.

Louten J, Rankin A, Li Y, Murphy E, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, de Waal Malefyt R. Endogenous IL-33 enhances Th2 cytokine production and T-cell response during allergic airway inflammation. Int Immunol 2011;23307–315

14.

Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227–33.PubMedCrossRef

15.

Carriere V, Roussel L, Ortega N, Lacorre DA, Amirich L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282–7.PubMedCrossRef

16.

Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2 V. Biochem Biophys Res Commun. 2001;285:1377–83.PubMedCrossRef

17.

Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, Kwak A, Hong K, Kim E, Jo S, Kim S. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem. 2011;286:20078–86.PubMedCrossRef

18.

Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002;32:1520–6.PubMedCrossRef

19.

Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 1999;190:895–902.PubMedCrossRef

20.

Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, Piedrafita D, Robinson JH, LIew FY. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787–94.PubMedCrossRef

21.

Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;965:6930–5.CrossRef

22.

Chan WL, Pejnovic N, Lee CA, Al-Ali NA. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol. 2001;167:1238–44.PubMed

23.

Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, Das A, Hogaboam CM. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010;11:52.PubMedCrossRef

24.

Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–30.PubMedCrossRef

25.

Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sigiyama Y. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277–81.PubMed

26.

Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73:206–12.PubMedCrossRef

27.

Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res. 2012;5:547–50.CrossRef

28.

Kamekura R, Kojima T, Takano K, Go M, Sawada N, Himi T. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy. 2012;42:218–28.PubMedCrossRef

29.

Ali S, Huber M, Kollewe C, BIschoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is Essentials for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104:18660–5.PubMedCrossRef

30.

Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel IL-33-LacZ gene trap reporter strain. J Immunol. 2012;188:3488–95.PubMedCrossRef

31.

Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol. 2011;43:1383–91.PubMedCrossRef

32.

Wisniewski JA, Borish L. Novel cytokines and cytokine-producing T cells in allergic disorders. Allergy Asthma Proc. 2011;32:83–94.PubMedCrossRef

33.

Oliphant C, Barlow JL, McKenzie A. Insights into the initiation of type 2 immune responses. Immunology. 2011;134:378–85.PubMedCrossRef

34.

Allakhverdi Z, Smith DE, Comeau M, Delespesse G. Cutting Edge: The ST2 ligand Il-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051–4.PubMed

35.

Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Tatsukata K, Yoshimasa I, Shigeharu F, Yasuda M, et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol. 2012;130:184–94.PubMedCrossRef

36.

Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, Nakae S. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971–8.PubMedCrossRef

37.

Kaieda S, Wang JX, Shnayder R, Fishgal N, Nei H, Lee RT, Stevens RL, Nigrovic PA. Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS One. 2012;7:e47252.PubMedCrossRef

38.

Suzukawa M, Likura M, Oketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsuhima K, Ohta K, Yamamto K, Yamaguchi M. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981–9.PubMed

39.

Pekaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct targer leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113:5981–9.

40.

Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–86.PubMedCrossRef

41.

• Kurowska-Stolarska M, Kewin P, Murphy G et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780–4790. In this study it was show that IL-33 may be involved in IL-4 independent Th2 cell differentiation.PubMed

42.

Chu DK, Llop-Guevara A, Walker TD, Flader K, Goncharova S, Boudreau JE, Moore CL, Waserman S, Coyle AJ, Kolbeck R, Humbles AA, Jordana M. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol. 2013;131:187–200.e8.PubMedCrossRef

43.

Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med. 1999;190:1541.PubMedCrossRef

44.

Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191:1069–76.PubMedCrossRef

45.

Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophils-mediated airway inflammation. J Immunol. 2010;185:3472–80.PubMedCrossRef

46.

Chow JY, Wong CK, Cheung PF, Lam CW. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol. 2010;7:26–34.PubMedCrossRef

47.

Na HJ, Hudson SA, Bochner BS. IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine. 2012;57:169–74.PubMedCrossRef

48.

Cherry WB, Yoon J, Bartemes KR, Lijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484–90.PubMedCrossRef

49.

Kim H, Jun C, Lee Y, et al. Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. J Allergy Clin Immunol. 2010;126:880.PubMedCrossRef

50.

Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. Il-33 and Il-33 receptors in host defense and diseases. Allergol Int. 2010;59:149–60.CrossRef

51.

Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, et al. Association of serum interleukin-22 level and the interleukin-33 genetic variant with Japanese Cedar pollinosis. Clin Exp Allergy. 2008;38:1875–81.PubMedCrossRef

52.

Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated Levels of Interleukin-33 in the Nasal Secretions of Patients with Allergic Rhinitis. Int Arch Allergy Immunol. 2012;158:47–50.PubMedCrossRef

53.

Eiwegger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol. 2011;41:1535–8.PubMedCrossRef

54.

• Kim Y.H, Yang T.Y, Park C.S, Ahn S.H, Son B.K, Kim J.H, Lim D.H, Jang T.Y. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012;67:183–190. The results of this experimental study provide an excellent framework for further research aimed at the improvement of allergy inflammation treatment. PubMedCrossRef

55.

Kearley J, Buckland KF, Mathic SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST1-IL-33 pathway. Am J Respir Crit Care Med. 2009;179:772–81.PubMedCrossRef

56.

Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibitis airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386:181–5.PubMedCrossRef

57.

Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363:1211–21.PubMedCrossRef

58.

Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, Chaudhuri R, Thomson NC, McKenzie ANJ, McInnes I, Liew FY, Xu D. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy. 2012;67:1118–26.PubMedCrossRef

59.

Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82:1481–90.PubMedCrossRef

60.

Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20:791–800.PubMedCrossRef

61.

Pushparaj PN, Tay HK, H’ng SC, Pitman N, Xu D, McKenzie A, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773–8.PubMedCrossRef

62.

Kitamura Y, Mizuguchi H, Ogishi H, Kuroda W, Hatttori M, Fukui H, Takeda N. Preseasonal prophylactic treatment with antihistamines suppresses Il-5 but not Il-33 mRNA expression in the nasal mucosa of patients with seasonal allergic rhinitis caused by Japanese cedar pollen. Acta Oto-Laryngologica. 2012;132:434–8.PubMedCrossRef

63.

Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, Martin JG. Hamid Q1 Increased expression in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;15:5094–103.CrossRef

64.

• Reh D, Wang Y, Ramanathan M, Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010;24:105–109. The first study to show evidence that Il-33 is produced by sinonasal epithelial cells derived from chronic sinusitis with nasal polyps, and Il-33 mRNA expression is several higher in patients with recalcitrant disease than those with a responsive disorder. PubMedCrossRef

65.

Leung BP, Xu D, Culshaw S, Mcinnes IB, Liew FY. A novel therapy of murine collagen – induced arthritis with soluble T1/ST2. J Immunol. 2004;173:145–50.PubMed

Title: The Role of Interleukin-33 in Rhinitis
Authors: Barbara Rogala
Joanna Glück
Publication date: 01-04-2013
Publisher: Current Science Inc.
Published in: Current Allergy and Asthma Reports / Issue 2/2013
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-013-0338-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Interleukin-33 in Rhinitis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Role of Fungi in the Pathophysiology of Chronic Rhinosinusitis: An Update

Comparative Analysis of Allergic Rhinitis in Children and Adults

Impact of Sleep as a Specific Marker of Quality of Life in Allergic Rhinitis

Gene Expression Signatures: A New Approach to Understanding the Pathophysiology of Chronic Rhinosinusitis

Oral Steroid Therapy in Chronic Rhinosinusitis with and without Nasal Polyposis

Role of Leukotriene Antagonists and Antihistamines in the Treatment of Allergic Rhinitis